NFKB1
Nuclear factor NF-kappa-B p105 subunit
As of the edition of 20 October 2026, NFKB1 (nuclear factor NF-kappa-B p105 subunit, UniProt P19838) has 3 drugs tested at it and 1 company on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P19838
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 15
- Disease areas
- Bones, joints and muscles; Inherited and neonatal; Nervous system; Cancer; Hormones; Nutrition and metabolism
- Registered trials of its drugs
- 8
Drugs at this target
| Status | Count |
|---|---|
| Stopped | 2 |
| Status not established | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Edasalonexent | Stopped | Phase 3 | none listed |
| CHS-828 | Stopped | Phase 1 | none listed |
| Cepharanthine | Status not established | Phase 2 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Undetermined | 1 |
| Total on the list | 1 |